Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides

IF 4.6 2区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Seminars in nuclear medicine Pub Date : 2024-07-01 DOI:10.1053/j.semnuclmed.2024.05.010

Richard P. Baum MD , Emil Novruzov MD , Tianzhi Zhao MD , Lukas Greifenstein MD , Vivianne Jakobsson MD , Elisabetta Perrone MD , Aditi Mishra MD , Aleksandr Eismant MD , Kriti Ghai MD , Ortwin Klein MD , Bastian Jaeschke MD , Daniel Benz-Zils PhD , Jens Cardinale PhD , Yuriko Mori PhD , Frederik L. Giesel MD , Jingjing Zhang MD

{"title":"Radiomolecular Theranostics With Fibroblast-Activation-Protein Inhibitors and Peptides","authors":"Richard P. Baum MD , Emil Novruzov MD , Tianzhi Zhao MD , Lukas Greifenstein MD , Vivianne Jakobsson MD , Elisabetta Perrone MD , Aditi Mishra MD , Aleksandr Eismant MD , Kriti Ghai MD , Ortwin Klein MD , Bastian Jaeschke MD , Daniel Benz-Zils PhD , Jens Cardinale PhD , Yuriko Mori PhD , Frederik L. Giesel MD , Jingjing Zhang MD","doi":"10.1053/j.semnuclmed.2024.05.010","DOIUrl":null,"url":null,"abstract":"<div>The advancement of theranostics, which combines therapeutic and diagnostic capabilities in oncology, has significantly impacted cancer management. This review explores fibroblast activation protein (FAP) expression in the tumor microenvironment (TME) and its association with various malignancies, highlighting its potential as a theranostic marker for PET/CT imaging using FAP-targeted tracers and for FAP-targeted radiopharmaceutical therapy. We examine the development and clinical applications of FAP inhibitors (FAPIs) and peptides, providing insights into their diagnostic accuracy, initial therapeutic efficacy, and clinical impact across diverse cancer types, as well as the synthesis of novel FAP-targeted ligands. This review aims to showcase the promising outcomes and challenges in integrating FAP-targeted approaches into cancer management.</div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"54 4","pages":"Pages 537-556"},"PeriodicalIF":4.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0001299824000515","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

The advancement of theranostics, which combines therapeutic and diagnostic capabilities in oncology, has significantly impacted cancer management. This review explores fibroblast activation protein (FAP) expression in the tumor microenvironment (TME) and its association with various malignancies, highlighting its potential as a theranostic marker for PET/CT imaging using FAP-targeted tracers and for FAP-targeted radiopharmaceutical therapy. We examine the development and clinical applications of FAP inhibitors (FAPIs) and peptides, providing insights into their diagnostic accuracy, initial therapeutic efficacy, and clinical impact across diverse cancer types, as well as the synthesis of novel FAP-targeted ligands. This review aims to showcase the promising outcomes and challenges in integrating FAP-targeted approaches into cancer management.

查看原文本刊更多论文

利用成纤维细胞活化蛋白抑制剂和多肽的放射分子疗法

治疗放射学结合了肿瘤学的治疗和诊断功能，其发展对癌症治疗产生了重大影响。这篇综述探讨了成纤维细胞活化蛋白（FAP）在肿瘤微环境（TME）中的表达及其与各种恶性肿瘤的关联，强调了它作为治疗标记物的潜力，可用于使用 FAP 靶向示踪剂的 PET/CT 成像以及 FAP 靶向放射性药物治疗。我们研究了 FAP 抑制剂（FAPIs）和多肽的开发和临床应用，深入探讨了它们在不同癌症类型中的诊断准确性、初步疗效和临床影响，以及新型 FAP 靶向配体的合成。本综述旨在展示将 FAP 靶向方法纳入癌症治疗过程中取得的丰硕成果和面临的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in nuclear medicine 医学-核医学

CiteScore

9.80

自引率

6.10%

发文量

审稿时长

14 days

期刊介绍： Seminars in Nuclear Medicine is the leading review journal in nuclear medicine. Each issue brings you expert reviews and commentary on a single topic as selected by the Editors. The journal contains extensive coverage of the field of nuclear medicine, including PET, SPECT, and other molecular imaging studies, and related imaging studies. Full-color illustrations are used throughout to highlight important findings. Seminars is included in PubMed/Medline, Thomson/ISI, and other major scientific indexes.